Evaluating SPH9788 Tablets in Healthy Adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study aims to assess the safety of SPH9788 tablets in healthy male and female participants aged 18 to 45 years. The study will involve administering SPH9788 and a placebo to evaluate any potential side effects or adverse reactions. Participants will be closely monitored throughout the trial to ensure their health and safety. The study is designed to gather important data on the pharmacokinetics of the drug in a controlled environment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Healthy male and female subjects aged from 18 to 45 years;
2. Subject has a Body Mass Index (BMI) between 18.5 and 28.0 kg/m2 at screening and the weight of male subjects is not less than 50 kg, and the weight of female subjects is not less than 45 kg;;
3. Subjects who voluntarily participate and sign informed consent form;
4. Subjects who can communicate well with investigator and comply with the lifestyle restrictions specified in the protocol, and cooperate to complete the trial procedure;
5. Subjects willing to use reliable contraceptive methods throughout the trial and for 6 months after trial completion.

Exclusion Criteria:

1. Medical history (current or past) that in the investigator's judgment may interfere with trial participation;
2. Surgical/medical conditions that may significantly affect drug pharmacokinetics (absorption, distribution, metabolism, excretion) or pose safety risks;
3. Occurrence of protocol-defined exclusionary events within 3 months prior to investigational product administration;
4. Use of any prescription/non-prescription medications (including herbal products) within 2 weeks prior to dosing;
5. Known hypersensitivity to any component of the investigational product or history of severe allergic reactions;
6. Positive serology for hepatitis B surface antigen, hepatitis C antibody, HIV antibody, and syphilis serum reaction;
7. Substance abuse history within 1 year prior to screening or positive urine drug screen;
8. Alcohol abuse history within 1 year or positive alcohol breath test;
9. Smoking ≥5 cigarettes/day on average during 3 months prior to screening;
10. Pregnant or lactating women;
11. Positive pregnancy test before study drug administration, or male and female subjects who refuse to use effective contraceptive methods during and for 6 months post-trial, or who have plans to donate sperm or eggs;
12. Poor compliance or any other condition that in the investigator's opinion renders the subject unsuitable for trial participation.

Where it's running

• Shanghai Mental Health Center
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Huafang Li
• Email: smhcirb@163.com
• Phone: 0086-021-34773308

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing SPH7485 tablets for advanced solid tumors

  This study is testing if SPH7485 tablets can help people with advanced solid tumors feel better and stay safe while taking the medication.

  Recruiting at 6 sites Phase 1 Shanghai Pharmaceuticals Holding Co., Ltd · Changsha and 5 other locations · NCT06487455

• Evaluating SPH7854 Granules in Healthy Individuals

  This study is testing the safety of SPH7854 granules in healthy people to see if there are any side effects compared to a placebo.

  Recruiting Early Phase 1 Shanghai Pharmaceuticals Holding Co., Ltd · Chengdu · NCT06483373

• Treatment of Her2-positive Biliary Tract or Colorectal Cancer with SPH5030 Tablets

  This study is testing if SPH5030 tablets can help people with advanced Her2-positive biliary tract or colorectal cancer feel better and manage their disease.

  Recruiting at 30 sites Phase 2 Shanghai Pharmaceuticals Holding Co., Ltd · Beijing and 29 other locations · NCT06434597

• Testing T3011 for advanced melanoma treatment

  This study is testing a new treatment called T3011 to see if it can help people with advanced melanoma feel better and manage their condition.

  Recruiting at 7 sites Phase 1/2 Shanghai Pharmaceuticals Holding Co., Ltd · Beijing and 6 other locations · NCT06214156

• Combining T3011 with PD-1/PD-L1 inhibitors for advanced solid tumors

  This study is testing if a new treatment called T3011, when combined with existing cancer drugs, can help people with advanced solid tumors feel better and improve their health.

  Recruiting at 22 sites Phase 1/2 Shanghai Pharmaceuticals Holding Co., Ltd · Anyang and 21 other locations · NCT06214143

• Evaluating SPH4336 alone or with Cadonilimab for advanced solid tumors

  This study is testing whether a new drug called SPH4336, alone or with another drug called Cadonilimab, can help people with advanced solid tumors who can't have surgery or other local treatments.

  Recruiting at 16 sites Phase 1/2 Shanghai Pharmaceuticals Holding Co., Ltd · Fuzhou, Fujian and 15 other locations · NCT05944224

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.